Virpax Pharmaceuticals has chosen Altasciences to conduct a first-in-human study of Epoladerm (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film.
The study will be conducted in the second quarter of 2022 at Altasciences’ clinical pharmacology unit in Montreal, Canada.
“We look forward to working with Altasciences to accelerate the development of this analgesic treatment and provide robust data in support of the 505(b)(2) FDA approval pathway,” stated Virpax’s Chairman & CEO, Anthony Mack.
Ingrid Holmes, Altasciences’ Vice President, Global Clinical Operations, said: “We are proud to partner with Virpax to help move this important therapeutic further along the path to regulatory approval.”